Completed OBSERVATIONAL NCT05812209

Stellate Ganglion Block to Treat Long COVID 19 Case Series

Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study

Sponsor: Metamorphosis LTD

Conditions Anosmia Brain Fog Cough Dizziness Dysautonomia Dysgeusia Fatigue Post Viral Long COVID Long Covid19 Menstrual Cycle Abnormal Muscle Pain Pain Post Acute COVID-19 Syndrome Post-COVID-19 Syndrome Shortness of Breath

Interventions Stellate Ganglion Block

Updated 3 times since 2023 Last updated: Apr 10, 2023 Started: Sep 1, 2022 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Anosmia and Brain Fog and is currently completed. Metamorphosis LTD leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2023 — Jul 2024 [monthly]

Completed

First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Metamorphosis LTD

Data source: Metamorphosis LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cañon City, United States